Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)

BACKGROUND: Immunotherapy has revolutionised the treatment of advanced cutaneous squamous cell carcinoma (cSCC). It is important to understand both safety and efficacy in a real-world and trial-ineligible cSCC population. We aimed to evaluate safety, efficacy and molecular insights among a broader c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Glenn J., Ruiz, Emily S., LeBoeuf, Nicole R., Thakuria, Manisha, Schmults, Chrysalyne D., Decaprio, James A., Silk, Ann W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653959/
https://www.ncbi.nlm.nih.gov/pubmed/32868898
http://dx.doi.org/10.1038/s41416-020-01044-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653959/
https://www.ncbi.nlm.nih.gov/pubmed/32868898
http://dx.doi.org/10.1038/s41416-020-01044-8

Ejemplares similares